Funding Opportunity PAR-25-171 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National cancer Institute (NCI) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this NOFO will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Notice NOT-DK-25-006 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-26-016 from the NIH Guide for Grants and Contracts. The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Enabling Technologies and Transformative Platforms initiative will support needed to rigorously validate transformative, multi-use platforms or technologies that can enable. Well-suited applications must offer the potential to significantly accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, behavior, prevention or epidemiology. Proposed platforms and technologies may have widespread applicability but must be able to improve the outlook for HLBS-related diseases and disorders.

Notice NOT-GM-25-003 from the NIH Guide for Grants and Contracts

Notice NOT-DK-25-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-290 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this NOFO.

Funding Opportunity PAR-25-291 from the NIH Guide for Grants and Contracts. Reissue of RFA-20-351.The purpose of this Notice of Funding Opportunity (NOFO) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this NOFO.

Funding Opportunity PAR-25-226 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

Notice NOT-HL-24-035 from the NIH Guide for Grants and Contracts

Competitive: Oxford Nanopore Technologies: Job Description Oxford Nanopore Technologies is headquartered at the Oxford Science Park outside Oxford, UK, with satellite offices and a commercial Oxford, Oxfordshire, United Kingdom

Funding Opportunity RFA-NR-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications from multidisciplinary teams of experts in firearm injury prevention research across departments and institutions to develop and provide research resources and support to build capacity among United States (U.S.) nurse researchers for rigorous, high-impact research in firearm injury prevention aligned with the NINR mission and scientific framework. These R24 awards are intended to: 1) build research resources that respond to the specific needs of the nurse researcher community; 2) train and attract new nurse researchers into the field; 3) support potential pilot project programs to accelerate research progress toward an NIH award; and 4) advance firearm injury prevention research infused with a social determinants and health equity perspective.

Funding Opportunity RFA-DA-26-017 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0-21 years old, as defined by the FDA Center for Devices and Radiological Health) affected by substance use and addiction.

Funding Opportunity RFA-DA-26-016 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0-21 years old, as defined by the FDA Center for Devices and Radiological Health) affected by substance use and addiction.

Funding Opportunity PAR-25-261 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

Funding Opportunity RFA-MH-26-111 from the NIH Guide for Grants and Contracts. Eradicating latent reservoirs of HIV-1 within the body and achieving a sterilizing or functional cure have become priority areas in the AIDS field and NIH AIDS programs across many Institutes and Centers, including NIMH. In addition understanding the mechanisms of HIV- associated co-morbidities in the setting of effective anti-retroviral therapy (ART) is a major topic of interest in the field. HIV Associated CNS (central nervous system) co-morbidities continue to exist despite excellent virologic control in this compartment. HIV persistence and neuroinflammation also continues to observed in the CNS in the setting of ART. HIV targets the CNS early in infection, and HIV-infected individuals suffer from mild forms of neurological impairments even under antiretroviral therapy (ART). CD4+ T cells and monocytes mediate HIV entry into the brain and constitute a source for HIV persistence and neuronal damage. CD8+ T cells are also massively recruited in the CNS in acute infection to control viral replication.

Funding Opportunity RFA-MH-26-110 from the NIH Guide for Grants and Contracts. Eradicating latent reservoirs of HIV-1 within the body and achieving a sterilizing or functional cure have become priority areas in the AIDS field and NIH AIDS programs across many Institutes and Centers, including NIMH. In addition understanding the mechanisms of HIV- associated co-morbidities in the setting of effective anti-retroviral therapy (ART) is a major topic of interest in the field. HIV Associated CNS (central nervous system) co-morbidities continue to exist despite excellent virologic control in this compartment. HIV persistence and neuroinflammation also continues to observed in the CNS in the setting of ART. HIV targets the CNS early in infection, and HIV-infected individuals suffer from mild forms of neurological impairments even under antiretroviral therapy (ART). CD4+ T cells and monocytes mediate HIV entry into the brain and constitute a source for HIV persistence and neuronal damage. CD8+ T cells are also massively recruited in the CNS in acute infection to control viral replication.

Notice NOT-MH-25-076 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-075 from the NIH Guide for Grants and Contracts

Notice NOT-AI-24-084 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-009 from the NIH Guide for Grants and Contracts